DIAGNOSTIC SIGNIFICANCE OF LIPOPROTEIN (A) LEVEL IN THE DEVELOPMENT OF CARDIOVASCULAR EVENTS
- 作者: Parshina S.A1, Sveklina T.S1
-
隶属关系:
- S.M. Kirov Military Medical Academy of the Ministry of Defense
- 期: 卷 39, 编号 1-1S (2020)
- 页面: 112-114
- 栏目: Articles
- URL: https://medbiosci.ru/RMMArep/article/view/43367
- DOI: https://doi.org/10.17816/rmmar43367
- ID: 43367
如何引用文章
全文:
详细
Currently, the quantitative level of lipoprotein (a) (Lp(a)) is becoming increasingly important, because even when the target levels of low-density lipoprotein cholesterol are reached, patients have a high risk of cardiovascular complications. The similarity of Lp(a) to low-density lipoproteins is in the presence of a Central core consisting of cholesterol esters and triglycerides surrounded by phospholipids. The structure of Lp(a) allows us to consider it as a participant in the processes of atherogenesis and thrombosis. There is a dose-dependent effect: the higher the concentration of Lp(a) in plasma, the more intense its accumulation in the vascular wall. Unlike other lipoproteins, the level of Lp(a) circulating in the blood is controlled by the apolipoprotein (a) gene. The purpose of this work was to determine the diagnostic value of the Lp(a) level in the development of cardiovascular events. 30 people were examined: 20 of them were patients with myocardial infarction or ischemic stroke more than 3 months ago and less than 10 years before the start of the study; the other 10 were a control group of healthy volunteers. All patients underwent a biochemical blood test to determine lipids and Lp(a). As a result, there was a direct correlation between Lp(a) levels with age, repeated cardiovascular events, HDL and LDL-C concentrations, and a negative relationship with triglyceride levels. Conclusions were made about the Association of high levels of Lp(a) with an increased risk of cardiovascular events in patients with established cardiovascular disease, and the need for further study of Lp(a) levels to determine the target value for the development and progression of cardiovascular diseases was identified.
作者简介
S. Parshina
S.M. Kirov Military Medical Academy of the Ministry of DefenseSt. Petersburg, Russia
T. Sveklina
S.M. Kirov Military Medical Academy of the Ministry of DefenseSt. Petersburg, Russia
参考
- Вельков, В.В. Липопротеин (а): новые перспективы для лабораторной диагностики / В.В. Вельков // Клинико-лабораторный консили-ум. - 2012. - №4 (44). - С.37-48.
- Гуревич, В.С. Соотношение количественных характеристик и функциональных свойств липопротеинов в атерогенезе. Обзор литера-туры / В.С. Гуревич [и др.] // Вестник СПбГУ. - 2014. - №1. - С.67-75.
- Зуева, И.Б. Липопротеин (а) как фактор сердечно-сосудистого риска. Современное состояние проблемы / И.Б. Зуева [и др.] // Вестник Российской Военно-медицинской академии. - 2017. - №1(57). - С.219-225.
- Зуева, И.Б. Современные представления о роли липопротеина (а) в развитии сердечно-сосудистых событий. Возможности терапии / И.Б. Зуева [и др.] // Артериальная гипертензия. - 2016. - №22(3). - С.232-243.
- Сафарова, М.С. Эволюция взглядов на липопротеид(а): от биомаркера до терапевтической мишени / М.С. Сафарова [и др.] // Кардиология. - 2015. - №55(4). - С.71-82.
- Kosmas, C.E. Therapeutic management of hyperlipoproteinemia (a) / C.E. Kosmas [et al.] // Drugs Context. - 2019. - №8. - P.1-11.
- Ward, N.C. Molecular, population, and clinical aspects of lipoprotein(a): a bridge too far? / N.C. Ward [et al.] // Journal of clinical medi-cine. - 2019. - №8(12). - P.1-23.
补充文件

